Author Interviews, Moderna, NEJM, Pharmaceutical Companies, Respiratory, Vaccine Studies / 13.12.2023

MedicalResearch.com Interview with: Eleanor Wilson, M.D Moderna, 200 Technology Sq. Cambridge, MA 02139 MedicalResearch.com: What is the background for this study? What are the main findings and side effects (if any)? Response: The ConquerRSV trial is a randomized, double-blind, placebo-controlled study of approximately 37,000 adults 60 years or older in 22 countries. The primary efficacy endpoints were based on two definitions of RSV-associated lower respiratory tract disease (RSV-LRTD) defined as either two or more symptoms, or three or more symptoms of disease. Vaccine efficacy was 83.7% (95.88% confidence interval [CI], 66.0 to 92.2) against RSV-associated lower respiratory tract disease with at least two signs or symptoms and 82.4% (96.36% CI, 34.8 to 95.3) against the disease with at least three signs or symptoms. Most adverse reactions were mild to moderate in severity and included injection site pain, fatigue, headache, myalgia, and arthralgia. (more…)
Aging, Author Interviews, Frailty, Infections / 18.11.2023

MedicalResearch.com Interview with: Hira Mohyuddin, PGY-2 Psychiatry Residency Training Program The George Washington University MedicalResearch.com: What is the background for this study? Response: Frailty has become increasingly significant as the global population grows older, as this syndrome is linked with a higher mortality and morbidity in aging. Causes contributing to frailty are poorly understood, but it seems that the role of inflammation is very likely. While other chronic infections were shown to precipitate and perpetuate inflammation that contributes to the development of frailty, no prior study has previously focused on possible links between Toxoplasma gondii and geriatric frailty. Benefiting from a collaboration with Spanish and Portuguese researchers, we have now tested, for the first time to our knowledge, this possible association. (more…)
Author Interviews, COVID -19 Coronavirus, Environmental Risks / 01.11.2023

MedicalResearch.com Interview with: Prof. Takeshi Asai Faculty of Health and Sports Sciences, University of Tsukuba, Tsukuba Japan Faculty of Physical Education, International Pacific University Okayama, Japan MedicalResearch.com: What is the background for this study? Response: In the early stages of the COVID-19 pandemic, contact and droplet transmission were considered the main routes of infection. However, it was later demonstrated that airborne transmission is an important route. Therefore, accumulating real-world data on airborne transmission was deemed crucial. (more…)
Author Interviews, COVID -19 Coronavirus, Pediatrics, Vaccine Studies / 01.11.2023

MedicalResearch.com Interview with: Anna Rosemarie Yousaf MD CDC: U.S. Centers for Disease Control and Prevention MedicalResearch.com: What is the background for this study? What are the main findings? Response: Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious complication following SARS-CoV-2 infection or COVID-19 illness in children characterized by fever and multiple organ inflammation. This study looks at data from children with MIS-C reported to CDC’s national MIS-C surveillance system and compares the characteristics of children who died to children who survived. (more…)
Author Interviews, COVID -19 Coronavirus, JAMA, Pediatrics / 26.10.2023

MedicalResearch.com Interview with: Neeraj Sood, PhD Verna and Peter Dauterive Hall University Park Campus University of Southern California Los Angeles, CA MedicalResearch.com: What is the background for this study? What are the main findings? Response: We conducted this study to inform school COVID-19 policies. The main findings are that the median duration of infectivity after a positive COVID-19 test in children is 3 days. The median duration of infectivity does not vary with vaccination.  (more…)
Author Interviews, Emory, Infections, JAMA, MRSA / 10.10.2023

MedicalResearch.com Interview with: Dr. John Jernigan, MD MS Clinical Associate Professor of Medicine Division of Infectious Diseases Emory University School of Medicine Branch Chief Epidemiology, Research and Innovations Branch CDC Center for Disease Control MedicalResearch.com: What is the background for this study? Response: Staphylococcus aureus commonly causes infections in ICUs. One approach to preventing these infections is using nasal mupirocin plus chlorhexidine gluconate (CHG) bathing for ICU patients. This practice is known to prevent methicillin-resistant Staphylococcus aureus (MRSA) infections and all-cause. bloodstream infections.  This practice has been broadly adopted in ICUs in the US, but adoption of mupirocin as a universal topical antibiotic has been slowed by concerns for engendering mupirocin resistance. This cluster-randomized trial in adult ICUs was conducted to assess whether universal nasal antiseptic povidone-iodine (iodophor), to which minimal S. aureus resistance is expected, was an acceptable alternative to universal nasal mupirocin for reducing S. aureus and MRSA clinical cultures in the setting of daily CHG bathing. Those who received chlorhexidine (CHG) bathing with mupirocin had an 18% reduction in risk of Staphylococcus aureus clinical cultures and a 15% reduction in risk of methicillin-resistant S. aureus (MRSA) clinical cultures compared to patients who received CHG bathing with intranasal iodophor.  These results show that using mupirocin for nasal decolonization may be preferred over iodophor because it is more effective at preventing S. aureus infections. (more…)
Author Interviews, HIV, JAMA, STD, USPSTF / 01.09.2023

MedicalResearch.com Interview with: James Stevermer, M.D., M.S.P.H.Vice chair for clinical affairs Professor of family and community medicine University of Missouri Medical director of MU Health Care Family Medicine–Callaway Physicians, Dr. Stevermer joined the U.S. Preventive Service Task Force in January 2021. MedicalResearch.com: What is the background for this study? Response: HIV continues to be a significant public health issue. The good news is that PrEP is a safe, highly effective way to help prevent HIV in people at increased risk. There are now two ways people can take PrEP – as a pill or as a shot. We encourage healthcare professionals to have a conversation with their patients about their individual risk for HIV and determine if they should consider taking whichever form of PrEP would work best for them. (more…)
Author Interviews, Biomarkers, Infections, Inflammation, Pediatrics / 18.08.2023

MedicalResearch.com Interview with: Myrsini Kaforou, PhD Senior Lecturer in Bioinformatics Department of Infectious Disease Imperial College London MedicalResearch.com: What is the background for this study? Response:  Children very often present to hospital and clinics with fever, but fever is a non-specific disease symptom. The identification of the cause of fever poses a great challenge for the clinical teams worldwide. The available diagnostic tests are neither quick or accurate enough to fully base decisions on, such as withholding or administering antibiotics. For example, cultures may take days or even weeks to provide a result. In our research group, we are working on novel approach; instead of trying to identify the causative pathogen, which is often inaccurate or impossible, we are studying the genes in the patient's blood that are "switched on" or "switched off" during the infection or the disease in general. Using computational/bioinformatics methods, we are able to identify out of thousands of genes, the combinations of genes, "the biosignatures" for each disease. In the past we had shown that this approach works to distinguish bacterial from viral infection, or tuberculosis disease from other conditions that mimic its symptoms. But with this work we have shown for the first time that a single set of genes, a "single gene panel" can be used to discriminate between 6 broad and/or 18 specific infectious or inflammatory conditions that cause fever in children. (more…)
Author Interviews, COVID -19 Coronavirus / 03.08.2023

MedicalResearch.com Interview with: Ayesha Lavell MD Universiteit Amsterdam, Department of Internal Medicine, Amsterdam Institute for Infection and Immunity Amsterdam, the Netherlands MedicalResearch.com: What is the background for this study? Response: Nose picking is so common in the overall population (91% in a survey study in the US, performed in 1995), maybe people find it hard to refrain from such a common behavior.  We were really curious whether this particular behavior would be more prone to infection spread, as it entails literally putting a potentially contaminate finger against the nasal mucosa. Also, previous research has shown us that nose picking is associated with nasal carriage of S. Aureus bacteria and volunteers have shown to be able to infect themselves with a common cold virus (Rhinovirus) by rubbing the virus inside their nose (laboratory based research in the early seventies). Therefore, it is surprising (given the amount of literature on SARS-CoV-2) that the relationship between nose picking and COVID-19 has not been studied before. And especially since health care workers are at increased risk of contracting SARS-CoV-2, we wanted to know more about common behavioral features that may contribute to this risk. (more…)
Author Interviews, COVID -19 Coronavirus, Environmental Risks / 27.07.2023

MedicalResearch.com Interview with:
Dr. Thomas Deliberto, PhD, DVM, APHIS Wildlife Services One Health Coordinator
  Dr. Thomas Deliberto, PhD, DVM, APHIS Wildlife Services One Health Coordinator     MedicalResearch.com: What is the background for this study? deer-covidResponse: In 2021, USDA launched a pilot study to investigate exposure of wild white-tailed deer (Odocoileus virginianus) to SARS-CoV-2, a zoonotic virus and the virus that causes COVID-19. Researchers found that 40% of the blood samples tested had SARS-CoV-2 antibodies. This initial study suggested that SARS-CoV-2 could be transmitted from humans to deer, and that deer could potentially serve as a reservoir for the virus. To better understand the transmission of SARS-CoV-2 in white-tailed deer, a team of researchers conducted a larger study to collect and analyze respiratory samples from free-ranging white-tailed deer in the United States.  The study identified SARS-CoV-2 sequences in white-tailed deer across nearly half of the states in the U.S. The researchers also found that deer could be infected with multiple SARS-CoV-2 lineages, and that these lineages could be transmitted from deer to deer. In addition, the researchers found three cases of potential virus transmission from white-tailed deer back to humans.  This raises concerns about the potential for the virus to continue to evolve in an animal reservoir, and the possibility of future spillover events. (more…)
Author Interviews, COVID -19 Coronavirus / 19.07.2023

MedicalResearch.com Interview with: Prof. Tommy Dickey Ph.D. Distinguished Professor Emeritus Geography Department University of California Santa Barbara Santa Barbara, CA covid-sniffing-dogs-tom-trainingMedicalResearch.com: What is the background for this study? Response:  I became interested in dog's sense of smell several years ago while doing therapy dog demonstrations at the California Science Center in Los Angeles during a special traveling exhibit "Dogs! A Science Tail." (Now at the Orlando Science Center).  I did a lot of research on this topic and taught children about it through the Los Angeles Public Library using my Great Pyrenees therapy dogs. Then, COVID broke out and I expanded my research into any work being done to possibly utilize scent dogs for screening and testing for COVID.  I found only a few such studies.  However, I fortuitously met Heather Junqueira of BioScent, Inc. (in Florida) online and she was beginning to successfully teach her beagles to detect COVID-related odors.  She agreed to co-author a peer-reviewed review paper with me.  That led to our first paper - Dickey, T, Junqueira, H. Toward the use of medical scent dogs for COVID-19 screening. J Osteopath Med 2021;1(2): 141-148. https://doi.org/10.1515/jom-2020-0222 When the COVID pandemic began to wane at the beginning of this year, I felt that it would be the perfect time to do this comprehensive follow-up review to see how far COVID scent dog research had progressed. To our amazement, research efforts had increased by almost tenfold and involved over 400 scientists using over 31,000 samples (including sniffings) from over 30 countries and that 29 peer reviewed papers had been published. Heather’s inspiration for doing scent dog work came when her father contracted cancer and she wanted to find better diagnostics.  She has since been successful in detecting non-small cell lung cancer with her trained beagles as well as COVID. (more…)
Author Interviews, COVID -19 Coronavirus / 10.07.2023

MedicalResearch.com Interview with: Fernanda Lessa, MD, MPH Chief, CDC’s International Infection Control Program Co-author of the paper MedicalResearch.com: What is the background for this study? What are the main findings? Response: Data from low- and middle-income countries on the impact of the COVID-19 pandemic on antibiotic use among outpatients are sparse. This study evaluated the changes in prescribing rates of antibiotics commonly prescribed for respiratory tract infections by outpatient providers among adults in Brazil. We observed increases during the pandemic in outpatient prescriptions of azithromycin and ceftriaxone of up 360% and 90%, respectively, based on age and sex. (more…)
Author Interviews, Infections, JAMA, NYU, USPSTF / 09.05.2023

MedicalResearch.com Interview with: Gbenga Ogedegbe, MD, MPH Dr. Adolph & Margaret Berger Professor of Population Health Director, Division of Health & Behavior Director Center for Healthful Behavior Change Department of Population Health NYU Langone Health NYU School of Medicine Member of the U.S. Preventive Services Task Force MedicalResearch.com: What is the background for this study? Response: Tuberculosis (TB) is a bacterial infection that is spread through the air from one person to another and usually affects the lungs. It’s a significant public health concern in the U.S. People can be infected with TB bacteria but not have any symptoms or be contagious, which is known as a latent TB infection or LTBI. If LTBI is left untreated, it can progress to active TB, which can cause serious health problems and become contagious. (more…)
Author Interviews, Breast Cancer, Cancer Research, JAMA, MRSA, Radiation Therapy / 06.05.2023

MedicalResearch.com Interview with: Beth McLellan, M.D. Chief, Division of Dermatology Montefiore Medical Center Albert Einstein College of Medicine MedicalResearch.com: What is the background for this study? How is the decolonization initiated and maintained? Response: We were interested in exploring whether bacteria on the skin plays a role in radiation dermatitis like it does in other skin diseases that cause a breakdown in the skin barrier. We used a bacterial decolonization regimen that includes chlorhexidine 2% cleanser for the body and mupirocin 2% ointment to the inside of the nose for 5 consecutive days before starting radiation therapy and repeated for an additional 5 days every other week for the duration of radiation. (more…)
Author Interviews, Urinary Tract Infections, Urology / 24.04.2023

MedicalResearch.com Interview with: Dr Jacqueline Stephens MPH, PhD Epidemiologist &  Senior lecturer Flinders University MedicalResearch.com: What is the background for this study? What are the main findings? Response: An increase in the volume of evidence published in the peer-reviewed literature on this topic prompted an update of this Cochrane Review. (more…)
Author Interviews, COVID -19 Coronavirus, Herpes Viruses, HIV, HPV, Infections, STD / 24.04.2023

MedicalResearch.com Interview with: Manoj Gandhi, MD PhD Senior Medical Director of Genetic Testing Services, Thermo Fisher Scientific. Dr. Gandhi has been working to advance the quality of medical care globally. Using his knowledge of Clinical Medicine and Molecular Biology/Pathology, he is focused on bridging these two fields and bringing innovative solutions that help advance science, the practice of medicine with the ultimate goal of impacting patient lives, whether it be in Infectious Diseases or Oncology or Personalized Medicine. This approach allows him to explore creative ways to utilize technology to help better identify diseases and improve the direction and value of treatment. MedicalResearch.com: What are the most common STIs prevalent in the US and worldwide today? Response: By far, the most common STIs in the US and worldwide is Human Papillomavirus (HPV) that can cause cervical cancer in women and Herpes Simplex Virus (HSV) that is the cause of genital herpes. Outside of these two major causes of STI, the others that are very common are Chlamydia, Gonorrhea, Trichomoniasis and Syphilis. It is important to note that the reported cases represent only a subset of the individuals with an infection as many may be asymptomatic and could be spreading these STIs to others. HIV is another STI that is common but usually rests in its own category due to its impact. (more…)
Annals Internal Medicine, Author Interviews, CDC, Infections / 29.03.2023

MedicalResearch.com Interview with: Dr. Meghan Lyman MD Medical Officer in the Mycotic Diseases Branch CDC MedicalResearch.com: What is the background for this study? Response: Candida auris (C. auris) is a fungus considered an urgent public health threat because it is often multi-drug resistant and spreads easily in healthcare settings.  CDC has been conducting tracking cases and is concerned about increasing numbers and geographic spread of C. auris cases in recent years, suggesting increased transmission.  Because C. auris cases and resistance are rising in the U.S., immediate public health actions to stop this threat are critical. (more…)
Aging, Author Interviews, Geriatrics, NEJM, Pulmonary Disease, Respiratory, Vaccine Studies / 09.03.2023

MedicalResearch.com Interview with: Veronica Hulstrøm MD, PhD Senior Director Clinical Project Lead for RSV Older Adults GSK     MedicalResearch.com: What is the background for this study? Response: The AReSVi-006 phase III trial is designed to investigate the efficacy and safety of GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. The phase III trial is a randomized, placebo-controlled, double-blind, international trial with 24,966 participants who received either the investigational vaccine or placebo. (more…)
Author Interviews, Infections, JAMA, OBGYNE, Pediatrics / 08.03.2023

MedicalResearch.com Interview with: Anna Roca PhD MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine Fajara, The Gambia MedicalResearch.com: What is the background for this study? Response: Context specific interventions are needed to decrease the high burden of severe neonatal morbidity and mortality in sub-Saharan Africa. Severe bacterial infections are a main cause of neonatal mortality in the continent. Oral intra-partum azithromycin is a cheap intervention easily scalable. Before embarking on this trial, we conducted a proof-of-concept trial that showed the intervention reduced maternal and neonatal bacterial carriage of the most prevalent bacteria causing neonatal sepsis in the continent. (more…)
Author Interviews, COVID -19 Coronavirus, Electronic Records, Health Care Systems, Race/Ethnic Diversity / 07.03.2023

MedicalResearch.com Interview with: Dhruv Khullar, M.D., M.P.P. Director of Policy Dissemination Physicians Foundation Center for Physician Practice and Leadership Assistant Professor of Health Policy and Economics Weill Cornell Medicine, NYC   MedicalResearch.com: What is the background for this study? Response: From prior research, we know that there are racial/ethnic differences in the acute impact of COVID-19, including higher rates of hospitalization and death among Black and Hispanic individuals compared to white individuals. Less is known about whether there are differences in the rates or types of long COVID by race and ethnicity. (more…)
Author Interviews, Infections, NIH, OBGYNE / 01.03.2023

MedicalResearch.com Interview with:
William A. Petri, MD PhDWilliam A. Petri, MD PhD Wade Hampton Frost Professor of Medicine and Vice Chair for Research of the Department of Medicine Professor of Medicine, Microbiology, Immunology and Cancer Biology, and Pathology, Medicine: Infectious Diseases and International Health, Medicine: Infectious Diseases and International Health
MedicalResearch.com: What is the background for this study? MedicalResearch.com We tested if prophylactic antibiotics could prevent sepsis and death in women in the late stages of normal vaginal labor and delivery. It was previously known that antibiotic were effective for this purpose in women undergoing C-section. The study was a randomized placebo-controlled trial at 8 international sites of nearly 30,000 women. (more…)
Author Interviews, COVID -19 Coronavirus, Nature, OBGYNE, Pediatrics / 28.02.2023

MedicalResearch.com Interview with: Dr Jessica Miller, PhD Murdoch Children’s Researcher and Professor David Burgner, Murdoch Children’s Group Leader, Infection and Immunity Murdoch Children’s Research Institute Royal Children's Hospital Victoria Australia   MedicalResearch.com: What is the background for this study? Response: Early reports following the initial COVID-19 lockdowns showed huge variation in changes to preterm birth and stillbirth rates, deeming it difficult to understand the pattern worldwide. It was uncertain if the observed variations were due to differences in study design and methodology, immediate impacts of lockdowns or changes in health service utilization. Previous reports from single populations or facilities were unlikely to be representative of the population and could not be compared across populations. Lockdowns affected health, social and economic factors that could lead to reductions in preterm birth rates. Changes in hygiene practices and abruptions to traffic following lockdown led to alterations in non-COVID infections and air pollution, which are known to trigger inflammation and contribute to preterm birth. Given the uncertainty in the earlier reports, we aimed to conduct a rigorous, standardised analysis using high-quality, total-population data from across the world in order to summarize and compare rates across countries. Our large global study included 52 million births between 2015-2020 from 26 countries and represents one of the first large-scale analyses of birth outcomes during the early months of COVID-19. (more…)
Author Interviews, Herpes Viruses, JAMA, STD, USPSTF / 23.02.2023

MedicalResearch.com Interview with: James Stevermer, M.D., M.S.P.H. Vice chair for clinical affairs Professor of family and community medicine University of Missouri Medical director of MU Health Care Family Medicine–Callaway Physicians, Dr. Stevermer joined the U.S. Preventive Service Task Force in January 2021.     MedicalResearch.com: What is the background for this study? Response: Genital herpes is a common sexually transmitted infection (STI) that unfortunately has no cure and cannot accurately be detected in people who do not have signs of the condition. The current screening tests have limitations and there is a high chance that test results will say a person has the condition when they do not. In addition, the available treatments are focused on managing symptoms and preventing the condition from reoccurring. As a result, the Task Force concluded that the harms of screening outweigh the benefits. (more…)
Author Interviews, COVID -19 Coronavirus, Race/Ethnic Diversity, Vaccine Studies / 10.02.2023

MedicalResearch.com Interview with: Kenya Colvin, MBS Department of Medical Education Scranton, PA MedicalResearch.com:  What is the background for this study?  Response: Vaccine hesitancy is a major driver of COVID-19 vaccination disparities between minority and non-Hispanic White communities. Our goal was to understand what factors influenced vaccine hesitancy among individuals in Eastern Pennsylvania to identify more effective ways to promote vaccine uptake within minority communities. (more…)
Addiction, Author Interviews, COVID -19 Coronavirus, Opiods / 07.02.2023

MedicalResearch.com Interview with: Brian Piper, PhD MS Assistant Professor of Neuroscience Center for Pharmacy Innovation & Outcomes Geisinger School of Graduate Education MedicalResearch.com: What is the background for this study? Response: Methadone is an evidence-based treatment of opioid use disorder (OUD) and pain. However, this Schedule II opioid can also cause respiratory depression, which can result in lethality. The need for supervised administration is a long-standing source of frustration in the U.S. for many opioid use disorder (OUD) methadone patients. However, there was an accommodation in early 2020 thanks to the COVID-19 pandemic. This involved extending the take-home supply to up to 28-days for stable patients and 14 days for less stable patients. Prior research found that the implementation of supervised administration in England greatly reduced methadone overdoses [1]. The primary objective of this study [2] from Geisinger Commonwealth School of Medicine was to determine if the relaxation of the take-home rules resulted in more methadone overdoses. (more…)
Author Interviews, Infections, NEJM, Pediatrics, Vaccine Studies / 02.02.2023

MedicalResearch.com Interview with: Manuel García Cenoz MD,  PhDInstituto de Salud Pública de Navarra - IdiSNA, Pamplona, SpainCIBER Epidemiología y Salud Pública, Madrid MedicalResearch.com: What is the background for this study? Response: Neisseria meningitidis is a major cause of severe disease in infants and children. After the introduction of serogroup C vaccines, serogroup B meningococcus has become the main cause of invasive meningococcal disease in Europe. The multicomponent protein-based meningococcal B vaccine (4CMenB, Bexsero, GSK) was licensed in the European Union in 2013. Its authorization was based on immunogenicity studies. Although some countries have introduced the 4CMenB vaccine into the publicly-funded infant immunization programs, the low incidence of the disease has limited the conduct of post-commercialization studies of effectiveness.Meningococcal B vaccine began to be used in Spain in children in 2014, recommended by the Spanish Association of Pediatrics, and paid by their families as it was not publicly-funded. We have conducted a nationwide study including all confirmed cases of invasive meningococcal disease in Spain between October 2015 and September 2019 in children aged two months to five years. (more…)
Author Interviews, Lancet, MRSA, NIH / 18.01.2023

MedicalResearch.com Interview with: Michael Otto PhD Senior Investigator Laboratory of Bacteriology Chief of the Pathogen Molecular Genetics Section NIAID, NIH Bethesda, MD 20814 MedicalResearch.com: What is the background for this study? Response:  Staphylococcus aureus is one the of the most important causes of infectious diseases worldwide. It is known mostly for causing skin infections in the community and as a hospital-associated pathogen. It is in fact the most frequent cause of infections patients acquire in the hospital when they are weakened by underlying diseases or immune-suppressing therapy. The type of infections Staph can cause in these situations are diverse – comprising bone, lung, and blood infections (sepsis) - and can be quite severe and often fatal. Except for moderately severe skin infections that may not require antibiotic treatment, treatment of Staph infections is by antibiotics. S. aureus has naturally been very responsive to penicillin-type antibiotics, but already in the mid of the last century, resistance to penicillin spread worldwide. Then, methicillin was invented to overcome this resistance, but nowadays there also is considerable spread of methicillin-resistant strains (MRSA). The current situation is difficult for two reasons:
  • First, S. aureus has become increasingly resistant to many antibiotics, and
  • Second, the alternatives to methicillin are often by far not as efficient as penicillin/methicillin against Staph.
Researchers have therefore been searching for alternatives to antibiotics to treat Staph infections. Unfortunately, vaccines that work against Staph have not yet been produced despite intensive efforts for decades. Other modern approaches of treatment, like virulence-targeted drugs or phages are still only at the early investigational level. As with many diseases, an alternative to treatment is prevention. In the case of S. aureus, a type of preventative strategy that has often been proposed and tested is decolonization. This is based on the fact that ~ 1/3 of the population is naturally colonized with S. aureus (asymptomatically), and these colonized people have an increased risk of being infected. In other words, Staph infections stem from the Staph you carry on your body and which only under certain conditions causes infection. Thus, eliminating the colonizing Staph would reduce the risk for infection, which is the basis for Staph decolonization-based infection prevention strategies. (more…)
Author Interviews, Genetic Research, Infections, Neurological Disorders / 14.12.2022

MedicalResearch.com Interview with: Dr. Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU) Chief Scientific Officer Population Bio UK, Inc. Begbroke Science Park Begbroke Hill Begbroke, Oxfordshire United Kingdom MedicalResearch.com: What is the background for this study? Response: Progressive Multifocal Leukoencephalopathy (PML) is a devastating condition that is associated with a number of clinical situations, including treatment with a variety of drugs. Of these, the best known is natalizumab (Tysabri), which is a very successful drug in the treatment of MS (multiple sclerosis). Only a small proportion of patients treated with natalizumab develop PML and this has always been a mystery. The study was based on a hypothesis that some individuals have an underlying susceptibility to developing PML, based on the presence of variants in genes that are important in the immune system. The study identified several of these variants. (more…)
Aging, Author Interviews, Brigham & Women's - Harvard, Dermatology, Heart Disease, Herpes Viruses, Stroke / 23.11.2022

MedicalResearch.com Interview with:| Sharon G. Curhan, MD, ScM| Director, CHEARS: The Conservation of Hearing Study Channing Division of Network Medicine Department of Medicine Brigham and Women’s Hospital Harvard Medical School Boston, MA 02114 MedicalResearch.com: What is the background for this study? Response:       Herpes zoster, commonly known as “shingles,” is a viral infection that often causes a painful rash. Shingles can occur anywhere on the head or body. Shingles is caused by the varicella zoster virus (VZV), the same virus that causes chickenpox. After a person has chickenpox, the virus stays in their body for the rest of their life. Years and even decades later, the virus may reactivate as shingles. Almost all individuals age 50 years and older in the US have been infected with the varicella zoster virus and therefore they are at risk for shingles. About 1 in 3 people will develop shingles during their lifetime, and since age is a risk factor for shingles, this number may increase as the population ages. The risk is also higher among individuals of any age who are immunocompromised due to disease or treatment. A number of serious complications can occur when a person develops shingles, such as post-herpetic neuralgia (long-lasting pain), but there was limited information on whether there are other adverse long-term health implications of developing shingles. There is a growing body of evidence that links VZV, the virus that causes shingles, to vascular disease. VZV vasculopathy may cause damage to blood vessels and increase the risk of stroke or coronary heart disease. Although some previous studies showed a higher risk of stroke or heart attack around the time of the shingles infection, it was not known whether this higher risk persisted in the long term. Therefore, the question we aimed to address in this study was to investigate whether shingles is associated with higher long-term risk of stroke or coronary heart disease. To address this question, we conducted a prospective longitudinal study in 3 large US cohorts of >200,000 women and men, the Nurses’ Health Study (>79,000 women), the Nurses’ Health Study II (almost 94,000 women) and the Health Professionals Follow-Up Study (>31,000 men), without a prior history of stroke or coronary heart disease. We collected information on shingles, stroke and coronary heart disease on biennial questionnaires and confirmed the diagnoses with medical record review. We followed the participants for up to 16 years and evaluated whether those who had developed shingles were at higher risk for stroke or coronary heart disease years after the shingles episode. The outcomes we measured were incident stroke, incident coronary heart disease [defined as having a non-fatal or fatal myocardial infarction (heart attack) or a coronary revascularization procedure (CABG, coronary artery bypass graft or percutaneous transluminal coronary angioplasty)]. We also evaluated a combined outcome of cardiovascular disease, which included either stroke or coronary heart disease, whichever came first. (more…)